The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort

Tatsuichiro Takahashi, Hiroyuki Uchida, Majnu John, Jinichi Hirano, Koichiro Watanabe, Masaru Mimura, Christoph U. Correll, Taishiro Kishimoto

Research output: Contribution to journalArticle

22 Citations (Scopus)


To examine the effect of prolactin-raising antipsychotics on bone mineral density (BMD), data of 164 schizophrenia patients who received ?. 2 dual-energy x-ray absorptiometry scans were analyzed (49.3% men; mean. ±. SD age: 58.5. ±. 11.0. years; duration of treatment: 26.7. ± 13.8. years). Patients were divided into a prolactin-raising antipsychotic (n = 141) or prolactin-sparing (n = 23) group, and time x group interaction was examined using mixed effect model. Although the BMD difference did not reach significance over 3.4. ± 1.6. years, a significant antipsychotic-class vs. time interaction was found (p = 0.011), indicating a negative impact of prolactin-raising antipsychotics on BMD. Large-scale, randomized-controlled data are required to replicate and extend these findings.

Original languageEnglish
Pages (from-to)383-386
Number of pages4
JournalSchizophrenia Research
Issue number2-3
Publication statusPublished - 2013 Jul 1



  • Antipsychotics
  • Bone mineral density
  • Dual-energy x-ray absorptiometry
  • Prolactin
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this